Showing 1541-1550 of 2150 results for "".
- DORC Launches New Range of EVA EquiPhaco Needles and Sleeveshttps://modernod.com/news/dorc-launches-new-range-of-eva-equiphaco-needles-and-sleeves/2477940/DORC announced the launch of a new range of EVA EquiPhaco needles and sleeves, which are designed to deliver superior ultrasound efficiency, improved anterior chamber stability, and easier sleeve positioning. T
- Diabetic Retinopathy Approaches Refined by New Trial Resultshttps://modernod.com/news/diabetic-retinopathy-approaches-refined-by-new-trial-results/2477686/Data from clinical trials are prompting leading diabetic retinopathy specialists to change their approach to treatment, according to a Medscape report. The Protocol studies conducted by the DRCR Retina Network, which is funded by t
- Eyewire News Exclusive: Q&A With Anne Coleman, MD, PhD, President of AAOhttps://modernod.com/news/eyewire-news-exclusive-qa-with-anne-coleman-md-phd-president-of-aao/2477474/The American Academy of Ophthalmology (AAO) continues to update its guidance for ophthalmologists dealing with the COVID-19 pandemic. Most recently, AAO updated its guidance on vaccine and t
- ProtoKinetix AAGP Retinal Cell Replacement Therapy Testing at UBC Completedhttps://modernod.com/news/protokinetix-aagp-retinal-cell-replacement-therapy-testing-at-ubc-completed/2477184/ProtoKinetix announced the completion of an in vivo study to assess the effect of AAGP on the long term survival and functional activity of photoreceptor precursor cells (PPCs) in the animal ocular model of genetic retinal degeneration. The objective of this study was to determine t
- Alimera Sciences Launches Iluvien in Germany For Noninfectious Uveitishttps://modernod.com/news/alimera-sciences-launches-iluvien-in-germany-for-noninfectious-uveitis/2476846/Alimera Sciences announced that it will immediately commence the launch of Iluvien in Germany for the prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIPU). Following the European Union’s Mutual Recognition Procedure in March 2019, Germany is t
- Johnson & Johnson Vision Launches New Surgical Vision Experience Center at the Johnson & Johnson Institute in Jacksonvillehttps://modernod.com/news/johnson-johnson-vision-launches-new-surgical-vision-experience-center-at-the-johnson-johnson-institute-in-jacksonville/2476784/Johnson & Johnson Vision announced today the launch of the Surgical Vision Experience Center at the Johnson & Johnson Institute in Jacksonville, Florida. The center will serve as Johnson & Johnson Vision’s premier physical t
- CHOP Researchers Develop Highly Specific Predictive Screening Tool for Retinopathy in Premature Infantshttps://modernod.com/news/chop-researchers-develop-highly-specific-predictive-screening-tool-for-retinopathy-in-premature-infants/2480024/A multi-hospital collaboration led by researchers at Children’s Hospital of Philadelphia (CHOP) has found a simple method of determining which premature infants should be screened for retinopathy of prematurity (ROP). The recommendations have the potential t
- New Type of Treatable Vertigo Identifiedhttps://modernod.com/news/new-type-of-treatable-vertigo-identified/2480140/Investigators have identified a new type of vertigo that may be treatable, according to a report in Medscape. This recurrent spontaneous vertigo (RSV) is not accompanied by neurologic symptoms and doesn’t satisfy the diagnosis
- SECO International Names Dr. R. Max Raynor as 2021 Presidenthttps://modernod.com/news/seco-international-names-dr-r-max-raynor-as-2021-president/2477497/SECO International has named R. Max Raynor, OD, as the next president. His term began on March 7, 2020, and will last through February 28, 2021. Dr. Raynor officially accepted the honor during the House of Delegates meeting held on Saturday, March 7 at SECO 20/20. “Dr. Raynor has dedicated
- Kalaris Therapeutics Launches Phase 1b/2 Dose-Finding Trial of TH103 for Wet AMDhttps://modernod.com/news/kalaris-therapeutics-launches-phase-1b2-dose-finding-trial-of-th103-for-wet-amd/2484144/Kalaris Therapeutics has initiated patient enrollment in a phase 1b/2 multiple ascending dose (MAD) clinical study of TH103, its investigational therapy for wet age-related macular degeneration (AMD). The phase 1b/2 t